The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles.

Highly viscoelastic and adhesive sputum has precluded efficient nanoparticle-based drug and gene delivery to the lungs of patients with cystic fibrosis (CF). We sought to determine whether nanoparticles coated with non-mucoadhesive polymers could penetrate CF sputum, and to use these "muco-inert particles" (MIPs) as non-destructive nanoprobes to characterize the sputum microstructure. Particles as large as 200 nm in diameter that were densely coated with low MW polyethylene glycol (PEG) moved through undiluted CF sputum with average speeds up to 90-fold faster than similarly-sized uncoated particles. On the other hand, the transport of both coated and uncoated 500 nm particles was strongly hindered. The local viscosity of sputum, encountered by the fastest 10% of 200 nm MIPs, was only 5-fold higher than that of water, whereas the bulk viscosity was 10,000-fold higher at low shear rates. Using measured transport rates of various sized MIPs combined with an obstruction-scaling model, we determined that the average 3D mesh spacing of CF sputum is approximately 140+/-50 nm (range: 60-300 nm). Taken together, these results demonstrate that nanoparticles up to 200 nm in diameter that do not adhere to CF sputum can move rapidly through this critical barrier by accessing pores that are filled with a low viscosity fluid. The results also offer hope that desperately needed sputum-penetrating drug- and gene-carrier nanoparticles can be developed for CF.

[1]  N A Peppas,et al.  Surface modifications and molecular imprinting of polymers in medical and pharmaceutical applications. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[2]  A. I. Yudin,et al.  Diffusion of macromolecules and virus-like particles in human cervical mucus. , 2001, Biophysical journal.

[3]  J. Suh,et al.  Quantifying the Intracellular Transport of Viral and Nonviral Gene Vectors in Primary Neurons , 2007, Experimental biology and medicine.

[4]  Denis Wirtz,et al.  Micro- and macrorheology of mucus. , 2009, Advanced drug delivery reviews.

[5]  P. Gilligan,et al.  Patterns of Epithelial Cell Invasion by Different Species of the Burkholderia cepacia Complex in Well-Differentiated Human Airway Epithelia , 2002, Infection and Immunity.

[6]  S. Smedt,et al.  Cystic fibrosis sputum: a barrier to the transport of nanospheres. , 2000, American journal of respiratory and critical care medicine.

[7]  N. Peppas,et al.  Design of poly(ethylene glycol)-tethered copolymers as novel mucoadhesive drug delivery systems. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[8]  Justin Hanes,et al.  Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus , 2007, Proceedings of the National Academy of Sciences.

[9]  K. Braeckmans,et al.  Three-dimensional fluorescence recovery after photobleaching with the confocal scanning laser microscope. , 2003, Biophysical journal.

[10]  D. Geddes,et al.  The extra- and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium , 1999, Gene Therapy.

[11]  Jung Soo Suk,et al.  Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. , 2008, Angewandte Chemie.

[12]  D. Clarke,et al.  Insertion of an Arginine Residue into the Transmembrane Segments Corrects Protein Misfolding* , 2006, Journal of Biological Chemistry.

[13]  D. Wirtz,et al.  Enhanced Viscoelasticity of Human Cystic Fibrotic Sputum Correlates with Increasing Microheterogeneity in Particle Transport* , 2003, Journal of Biological Chemistry.

[14]  E. Fedorov,et al.  Multiple-particle tracking measurements of heterogeneities in solutions of actin filaments and actin bundles. , 2000, Biophysical journal.

[15]  Kevin B. Johnson,et al.  Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease , 2008, Journal of Pharmacology and Experimental Therapeutics.

[16]  B. Rubin Other medications for aerosol delivery. , 2006, Paediatric respiratory reviews.

[17]  S. Randell,et al.  Evidence for Periciliary Liquid Layer Depletion, Not Abnormal Ion Composition, in the Pathogenesis of Cystic Fibrosis Airways Disease , 1998, Cell.

[18]  T. Flotte,et al.  Gene therapy in cystic fibrosis. , 1999, Chest.

[19]  Russell M. Taylor,et al.  A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms , 2006, Proceedings of the National Academy of Sciences.

[20]  T. Kirikae,et al.  Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. , 2005, Chest.

[21]  M. Knowles,et al.  Mucus clearance and lung function in cystic fibrosis with hypertonic saline. , 2006, The New England journal of medicine.

[22]  R. Boucher,et al.  Cystic Fibrosis: The Mechanisms of Pathogenesis of an Inherited Lung Disorder. , 2007, Drug discovery today. Disease mechanisms.

[23]  D. Leckband,et al.  Direct Measurement of Interactions between Tethered Poly(ethylene glycol) Chains and Adsorbed Mucin Layers , 2002 .

[24]  M. Drumm,et al.  Cystic fibrosis. , 1996, American journal of respiratory and critical care medicine.

[25]  D. Wirtz,et al.  Efficient active transport of gene nanocarriers to the cell nucleus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Porteous,et al.  Non-viral vectors in cystic fibrosis gene therapy: progress and challenges. , 2004, Trends in biotechnology.

[27]  A. Hickey,et al.  Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy. , 2002, Advanced drug delivery reviews.

[28]  Junghae Suh,et al.  Real-time multiple-particle tracking: applications to drug and gene delivery. , 2005, Advanced drug delivery reviews.

[29]  S. Randell,et al.  Reduced Three-Dimensional Motility in Dehydrated Airway Mucus Prevents Neutrophil Capture and Killing Bacteria on Airway Epithelial Surfaces1 , 2005, The Journal of Immunology.

[30]  J. Voynow,et al.  Respiratory tract mucin genes and mucin glycoproteins in health and disease. , 2006, Physiological reviews.

[31]  J. Suh,et al.  Gene Delivery to the Lung , 2003 .

[32]  A. Hoffman,et al.  Mucoadhesive drug carriers based on complexes of poly(acrylic acid) and PEGylated drugs having hydrolysable PEG-anhydride-drug linkages. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[33]  W. Saltzman,et al.  DNA diffusion in mucus: effect of size, topology of DNAs, and transfection reagents. , 2006, Biophysical journal.

[34]  A. Hickey,et al.  Aerosol treatment of cystic fibrosis. , 2003, Critical reviews in therapeutic drug carrier systems.

[35]  P. Noone,et al.  Sodium channel blockers for cystic fibrosis. , 2006, The Cochrane database of systematic reviews.

[36]  F. Ratjen,et al.  Mucolytics in cystic fibrosis. , 2007, Paediatric respiratory reviews.

[37]  P. Quinton Physiological basis of cystic fibrosis: a historical perspective. , 1999, Physiological reviews.

[38]  B. Amsden,et al.  An Obstruction-Scaling Model for Diffusion in Homogeneous Hydrogels , 1999 .

[39]  B. Laube,et al.  The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. , 2005, Respiratory care.

[40]  A. Verkman,et al.  Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease. , 2003, American journal of physiology. Cell physiology.

[41]  J. Hanes,et al.  Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. , 2009, Advanced drug delivery reviews.

[42]  James R. Smith,et al.  Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. , 2007, Pulmonary pharmacology & therapeutics.